contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


vicore-to-present-at-the-jefferies-global-healthcare-conference

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Vicore Pharma är verksamt inom läkemedelsbranschen och fokuserar på utveckling av innovativa behandlingar för lung- och hjärt-kärlsjukdomar. Bolaget forskar på nya terapier som kan förbättra patientresultat och livskvalitet. Verksamheten är global med en huvudsaklig närvaro i Europa och Nordamerika. Vicore Pharma grundades 2000 och har sitt huvudkontor i Göteborg.

Vicore Pharma Holding

Stockholm, May 28, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation...

<div class="mfn-body">Stockholm, May 28, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the Jefferies Global Healthcare Conference:<ul><li>Location: New York, USA</li><li>Format: Presentation and 1x1 meetings</li><li>Presentation Date and Time: Thursday, June 5 at 4:20 PM ET</li><li>Webcast: <a rel="noopener" href="https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwsw.com%2Fwebcast%2Fjeff319%2Fvico%2F1857304&amp;data=05%7C02%7Cmegan.richards%40vicorepharma.com%7C650a54ec91e34ae43b5e08dd7d0dd668%7Ce2b856873a23456bb473172f1555f948%7C0%7C0%7C638804220582481997%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=YNpfvw3dEu1xuJqmXqISW72P3C5AY04JS964XYnoTZg%3D&amp;reserved=0">https://wsw.com/webcast/jeff319/vico/1857304</a></li><li>Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR </li></ul>The company’s management will also be available for meetings at the conference. Interested parties may access the webcast replay on the&nbsp;<a rel="noopener" href="https://vicorepharma.com/investors/events-presentations/">Events &amp; Presentations</a>&nbsp;page of Vicore’s website for 90 days following the conclusion of the event. &nbsp; For further information, please contact: Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1&nbsp;978&nbsp;269-4372, <a rel="noopener" href="mailto:megan.richards@vicorepharma.com">megan.richards@vicorepharma.com</a> &nbsp;&nbsp; Hans Jeppsson, CFO, tel: +46 70 553 14 65, <a rel="noopener" href="mailto:hans.jeppsson@vicorepharma.com">hans.jeppsson@vicorepharma.com</a> &nbsp; About Vicore Pharma&nbsp; Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA) and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.&nbsp; &nbsp; The company is publicly listed on the Nasdaq Stockholm exchange (VICO). <a rel="noopener" href="http://www.vicorepharma.com/">www.vicorepharma.com</a>&nbsp;</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments <a rel="noopener" href="https://storage.mfn.se/e2749194-f6a2-4c9a-9204-8697159083c9/vicore-to-present-at-the-jefferies-global-healthcare-conference.pdf" class="mfn-generated mfn-primary">Vicore to Present at the Jefferies Global Healthcare Conference</a></div>